Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment
Medulloblastoma displays subtype-specific expressions of FDA-approved TKI, ICI and pro-apoptotic drug targets, impacting overall survival. Clinical trials investigating these approved treatments in medulloblastoma are therefore warranted.
Authors
- Clémence Fournier (ORCID: https://orcid.org/0000-0002-3569-3690)
- Gilles Pagès (ORCID: https://orcid.org/0000-0002-8466-5610)
- Arthur Karaulic (ORCID: https://orcid.org/0009-0008-0612-5898)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-14
- DOI
- https://doi.org/10.3390/cancers17223659
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00